Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGFβi NK cells
- Development stage
- Unknown
- Lead developer
- Nationwide Children's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intracavitary, Intratumoral
01
Overview
TGFβi NK cells are an investigational cell-based immunotherapy developed by Nationwide Children's Hospital for the treatment of recurrent or refractory high-grade gliomas and other malignant pediatric brain tumors. These are universal donor (UD) natural killer (NK) cells that have been ex vivo expanded and engineered to express a dominant negative TGF-β receptor (dnTGFβRII) which lacks the intracellular kinase domain. This modification renders the NK cells insensitive to the immunosuppressive effects of TGF-β, a cytokine prevalent in the brain tumor microenvironment that typically inhibits immune responses. By bypassing this suppression, the cells maintain their cytotoxic potential against tumor cells. The therapy is delivered locoregionally via an Ommaya reservoir or a programmable ventriculoperitoneal (VP) shunt directly into the tumor cavity or resection site.
- Other names
- Transforming growth factor beta imprinted Natural Killer cellsdnTGFβRII NK cellsUniversal donor TGFβi NK cells
Beyond the preview
Go deeper on TGFβi NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGFβi NK cells.